HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.

AuthorsTina Roy, Joseph B An, Kimberly Doucette, Aimee M Chappell, David H Vesole
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 63 Issue 3 Pg. 759-761 (03 2022) ISSN: 1029-2403 [Electronic] United States
PMID35076333 (Publication Type: Letter)
Chemical References
  • Antineoplastic Agents
  • BCL2 protein, human
  • Bridged Bicyclo Compounds, Heterocyclic
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • venetoclax
Topics
  • Antineoplastic Agents (therapeutic use)
  • Bridged Bicyclo Compounds, Heterocyclic (pharmacology, therapeutic use)
  • Humans
  • Induction Chemotherapy
  • Leukemia, Plasma Cell (diagnosis, drug therapy, genetics)
  • Proto-Oncogene Proteins c-bcl-2 (genetics, metabolism)
  • Sulfonamides

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: